M. Maccoss

发表

Rings in drugs.

Richard D. Taylor, M. Maccoss, A. Lawson, 2014, Journal of medicinal chemistry.

Organic Chemistry in Drug Discovery

T. Baillie, M. Maccoss, Malcolm MacCoss, 2004, Science.

Combining Molecular Scaffolds from FDA Approved Drugs: Application to Drug Discovery.

Richard D. Taylor, M. Maccoss, A. Lawson, 2017, Journal of medicinal chemistry.

Characterization of a Novel, Non-peptidyl Antagonist of the Human Glucagon Receptor*

M. Maccoss, C. Hacker, S. D. de Laszlo, 1999, The Journal of Biological Chemistry.

Importance of Rigidity in Designing Small Molecule Drugs To Tackle Protein-Protein Interactions (PPIs) through Stabilization of Desired Conformers.

M. Maccoss, A. Lawson, J. Heer, 2017, Journal of medicinal chemistry.

Inhibition of interleukin-1β converting enzyme by N-acyl-aspartyl aryloxymethyl ketones

M. Maccoss, N. Thornberry, E. Peterson, 1995 .

Pyridofuran substituted pyrimidine derivatives as HCV replication (replicase) inhibitors.

X. Tong, M. Maccoss, R. Reynolds, 2012, Bioorganic & medicinal chemistry letters.

5-Benzothiazole substituted pyrimidine derivatives as HCV replication (replicase) inhibitors.

X. Tong, M. Maccoss, R. Reynolds, 2012, Bioorganic & medicinal chemistry letters.

N-Tetrahydrofuroyl-(L)-phenylalanine derivatives as potent VLA-4 antagonists.

M. Maccoss, S. D. de Laszlo, Bing Li, 2002, Bioorganic & medicinal chemistry letters.

Substituted tetrahydrofuroyl-1-phenylalanine derivatives as potent and specific VLA-4 antagonists.

M. Maccoss, W. Hagmann, John A. Schmidt, 2002, Bioorganic & medicinal chemistry letters.

The discovery of sulfonylated dipeptides as potent VLA-4 antagonists.

M. Maccoss, S. D. de Laszlo, J. Fenyk-Melody, 2001, Bioorganic & medicinal chemistry letters.

Amidines as amide bond replacements in VLA-4 antagonists.

M. Maccoss, S. D. de Laszlo, W. Hagmann, 2004, Bioorganic & medicinal chemistry letters.

Substituted 3-amino biaryl propionic acids as potent VLA-4 antagonists.

M. Maccoss, W. Hagmann, K. Lyons, 2002, Bioorganic & medicinal chemistry letters.

Specific and dual antagonists of α4β1 and α4β7 integrins

M. Maccoss, W. Hagmann, L. Lin, 2002 .

The discovery of acylated beta-amino acids as potent and orally bioavailable VLA-4 antagonists.

M. Maccoss, S. D. de Laszlo, J. Fenyk-Melody, 2002, Bioorganic & medicinal chemistry letters.

Robust Antiviral Efficacy upon Administration of a Nucleoside Analog to Hepatitis C Virus-Infected Chimpanzees

D. Hazuda, D. Graham, M. Maccoss, 2008, Antimicrobial Agents and Chemotherapy.

Synthesis and biological evaluation of platensimycin analogs.

M. Maccoss, Hong C Shen, S. Soisson, 2009, Bioorganic & medicinal chemistry letters.

Synthesis of 2′-β-C-methyl-neplanocin derivatives as anti-HCV agents

M. Maccoss, G. Butora, D. Olsen, 2008 .

Phospholipid-nucleoside conjugates. 5. The interaction of selected 1-beta-D-arabinofuranosylcytosine-5'-diphosphate-L-1,2-diacylglycerols with serum lipoproteins.

J. J. Edwards, M. Maccoss, Y. Rahman, 1983, Biochemical and biophysical research communications.

Inhibition of interleukin-1β converting enzyme by N-Acyl-aspartic acid ketones

M. Maccoss, N. Thornberry, E. Peterson, 1995 .

An expeditious synthesis of 3-(difluoromethoxy)- and 3-(trifluoromethoxy)-5,6,7,8-tetrahydro-1,6-naphthyridines

M. Maccoss, D. Guiadeen, S. Kothandaraman, 2008 .

N-aryl-prolyl-dipeptides as potent antagonists of VLA-4.

M. Maccoss, S. D. de Laszlo, Bing Li, 2002, Bioorganic & medicinal chemistry letters.

1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists. Part 4: synthesis of N-1 acidic functionality affording analogues with enhanced antiviral activity against HIV.

D. Hazuda, W. Schleif, E. Emini, 2002, Bioorganic & medicinal chemistry letters.

Activated ketones as potent reversible inhibitors of interleukin-Iβ converting enzyme

M. Maccoss, N. Thornberry, E. Peterson, 1994 .

Phenylalkyl ketones as potent reversible inhibitors of interleukin-1β converting enzyme

M. Maccoss, N. Thornberry, K. Chapman, 1993 .

Synthesis of a peptidyl 2,2-difluoro-4-phenylbutyl ketone and its evaluation as an inhibitor of interleukin-1β converting enzyme.

M. Maccoss, K. Chapman, A. Mjalli, 1993 .

The discovery of a potent and selective lethal factor inhibitor for adjunct therapy of anthrax infection.

E. Scolnick, A. Woods, D. Zaller, 2006, Bioorganic & Medicinal Chemistry Letters.

Orally active inhibitors of stromelysin-1 (MMP-3)

M. Maccoss, W. Hagmann, K. Chapman, 1996 .

Syntheses and SAR studies of 4-(heteroarylpiperdin-1-yl-methyl)-pyrrolidin-1-yl-acetic acid antagonists of the human CCR5 chemokine receptor.

D. Hazuda, W. Schleif, E. Emini, 2004, Bioorganic & Medicinal Chemistry Letters.

Syntheses and biological evaluation of 5-(piperidin-1-yl)-3-phenyl-pentylsulfones as CCR5 antagonists.

D. Hazuda, Ping Chen, W. Schleif, 2004, Bioorganic & medicinal chemistry letters.

1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists: modifications of the arylpropylpiperidine side chains.

D. Hazuda, Ping Chen, W. Schleif, 2003, Bioorganic & medicinal chemistry letters.

CCR5 antagonists: bicyclic isoxazolidines as conformationally constrained N-1-substituted pyrrolidines.

D. Hazuda, W. Schleif, E. Emini, 2002, Bioorganic & medicinal chemistry letters.

Discovery and Characterization of Potent, Efficacious, Orally Available Antimalarial Plasmepsin X Inhibitors and Preclinical Safety Assessment of UCB7362

Richard D. Taylor, D. Goldberg, A. Cowman, 2022, Journal of medicinal chemistry.

Discovery of N-{N-[(3-cyanophenyl)sulfonyl]-4(R)-cyclobutylamino-(L)-prolyl}-4-[(3',5'-dichloroisonicotinoyl) amino]-(L)-phenylalanine (MK-0668), an extremely potent and orally active antagonist of very late antigen-4.

P. Davies, M. Maccoss, C. Raab, 2009, Journal of medicinal chemistry.

Inhibition of matrix metalloproteinases by N-carboxyalkyl dipeptides: Enhanced potency and selectivity with substituted P1′ homophenylalanines

M. Maccoss, W. Hagmann, K. Chapman, 1995 .

Design, synthesis, and structure-activity relationship of novel CCR2 antagonists.

M. Struthers, M. Maccoss, J. Demartino, 2009, Bioorganic & medicinal chemistry letters.

Phospholipid-nucleoside conjugates. The aggregational characteristics and morphological aspects of selected 1-beta-D-arabinofuranosylcytosine 5'-diphosphate-L-1,2-diacylglycerols.

J. J. Edwards, M. Maccoss, S. Spragg, 1982, Biochimica et biophysica acta.

Conformational flexibility of the 3' acceptor end of transfer ribonucleic acid.

S. Danyluk, M. Maccoss, R. Sarma, 1980, Biochemistry.

Rings in Clinical Trials and Drugs: Present and Future

Richard D. Taylor, M. Maccoss, A. Lawson, 2022, Journal of medicinal chemistry.

Characterization of the binding and activity of a high affinity, pseudoirreversible morpholino tachykinin NK1 receptor antagonist.

C. Strader, M. Tota, M. Maccoss, 1997, European journal of pharmacology.

1,2,4-Triacylpiperidine substance p antagonists: Separation of affinities for the NK-1 receptor and the L-type calcium channel

M. Maccoss, P. Hutson, Smita Patel, 1995 .

1,4-Diacylpiperazine-2-(S)-[(N-aminoalkyl)carboxamides] as novel, potent substance P receptor antagonists.

C. Strader, W. Greenlee, M. Maccoss, 1993 .

Substituted 2-aminopyridines as inhibitors of nitric oxide synthases.

M. Maccoss, W. Hagmann, S. Grant, 2000, Bioorganic & medicinal chemistry letters.

Phospholipid derivatives of nucleoside analogs as prodrugs with enhanced catabolic stability.

M. Maccoss, C. Hong, T. Matsushita, 1981, Cancer research.

The synthesis, characterization, and preliminary biological evaluation of 1-beta-D-arabinofuranosylcytosine-5'-diphosphate-L-1,2-dipalmitin.

M. Maccoss, T. Matsushita, E. Ryu, 1978, Biochemical and biophysical research communications.

N-Tetrahydrofuroyl-(L)-phenylalanine derivatives as potent VLA-4 antagonists.

M. Maccoss, S. D. de Laszlo, W. Hagmann, 2002, Bioorganic & medicinal chemistry letters.

Bicyclic amidine inhibitors of nitric oxide synthase: discovery of perhydro-iminopyrindine and perhydro-iminoquinoline as potent, orally active inhibitors of inducible nitric oxide synthase.

M. Maccoss, S. Grant, R. Chabin, 2005, Bioorganic & medicinal chemistry letters.

Robust Antiviral Efﬁcacy upon Administration of a Nucleoside Analog to Hepatitis C Virus-Infected Chimpanzees (cid:1)

D. Hazuda, D. Graham, M. Maccoss, 2009 .

Modification of the Dittmer-Lester reagent for the detection of phospholipid derivatives on thin-layer chromatograms.

M. Maccoss, E. Ryu, 1979, Journal of lipid research.

Anticancer pyrimidines, pyrimidine nucleosides and prodrugs

M. Maccoss, M. Robins, 1990 .

Structure-activity relationship of heterobase-modified 2'-C-methyl ribonucleosides as inhibitors of hepatitis C virus RNA replication.

P. D. Cook, J. Tomassini, M. Maccoss, 2004, Journal of medicinal chemistry.

Sustained Viral Response in a Hepatitis C Virus-Infected Chimpanzee via a Combination of Direct-Acting Antiviral Agents

D. Hazuda, D. Graham, M. Maccoss, 2010, Antimicrobial Agents and Chemotherapy.

Phosphoramidate prodrugs of 2'-C-methylcytidine for therapy of hepatitis C virus infection.

S. Harper, M. Maccoss, F. Narjes, 2009, Journal of medicinal chemistry.

Liver-targeted prodrugs of 2'-C-methyladenosine for therapy of hepatitis C virus infection.

M. Erion, P. D. van Poelje, M. Maccoss, 2007, Journal of medicinal chemistry.

Inhibition of human purine nucleoside phosphorylase by acyclic nucleosides and nucleotides.

J. D. Karkas, M. Maccoss, R. Tolman, 1987, Biochemical Pharmacology.

Synthesis and HCV inhibitory properties of 9-deaza- and 7,9-dideaza-7-oxa-2'-C-methyladenosine.

M. Maccoss, G. Butora, D. Olsen, 2007, Bioorganic & medicinal chemistry.

L-tryptophan urea amides as NK1/NK2 dual antagonists.

M. Maccoss, M. Cascieri, S. Sadowski, 1998, Bioorganic & medicinal chemistry letters.

Mechanism of inhibition of human leucocyte elastase by monocyclic beta-lactams.

M. Maccoss, W. Hagmann, R. Chabin, 1993, Biochemistry.

Determination of the Karplus relationships for the C‐2, H‐1′ and C‐6, H‐1′ vicinal coupling paths of uridine derivatives

S. Danyluk, M. Maccoss, D. Davies, 1985 .

4-Amino-2-alkyl-butyramides as small molecule CCR2 antagonists with favorable pharmacokinetic properties.

M. Maccoss, G. Butora, D. Guiadeen, 2006, Bioorganic & medicinal chemistry letters.

Discovery of 3,5-bis(trifluoromethyl)benzyl L-arylglycinamide based potent CCR2 antagonists.

M. Maccoss, W. Hanlon, G. Butora, 2006, Bioorganic & medicinal chemistry letters.

Synthesis of new imidazo[1,2-b]pyridazine isosteres of potent imidazo[4,5-b]pyridine angiotensin II antagonists

W. Greenlee, R. Chang, V. J. Lotti, 1994 .

New procedure for the chlorination of pyrimidine and purine nucleosides

M. Maccoss, E. Ryu, 1981 .

Synthesis and evaluation of CCR5 antagonists containing modified 4-piperidinyl-2-phenyl-1-(phenylsulfonylamino)-butane.

D. Hazuda, W. Schleif, E. Emini, 2005, Bioorganic & medicinal chemistry letters.

Synthesis of analogs of (1,4)-3- and 5-imino oxazepane, thiazepane, and diazepane as inhibitors of nitric oxide synthases.

Kenny K. Wong, Ping Chen, M. Maccoss, 2004, Bioorganic & medicinal chemistry letters.

The discovery of small molecule carbamates as potent dual α4β1/α4β7 integrin antagonists

M. Maccoss, W. Hagmann, K. Lyons, 2002 .

A new aspect of the use of 2′,3′-O-isopropylidene ribonucleosides for investigation of anomeric configuration☆

M. Maccoss, B. Rayner, J. Imbach, 1977 .

M. Maccoss, M. Robins, G. Ramani, 1975 .

Syntheses of 4- and 6-substituted thiazolo[4,5-c]pyridines

M. Senior, M. Maccoss, N. Bansal, 2010 .

Synthesis and hypoglycemic activity of substituted 8-(1-piperazinyl)imidazo[1,2-a]pyrazines.

M. Maccoss, R. Tolman, R Saperstein, 1992, Journal of medicinal chemistry.

A 7-Deaza-Adenosine Analog Is a Potent and Selective Inhibitor of Hepatitis C Virus Replication with Excellent Pharmacokinetic Properties

Giovanni Migliaccio, D. Hazuda, J. Tomassini, 2004, Antimicrobial Agents and Chemotherapy.

Potent, orally absorbed glucagon receptor antagonists.

M. Maccoss, C. Hacker, S. D. de Laszlo, 1999, Bioorganic & medicinal chemistry letters.

Pyrroles and other heterocycles as inhibitors of p38 kinase.

M. Maccoss, B. Frantz, G. Croft, 1998, Bioorganic & medicinal chemistry letters.

Discovery of 3-piperidinyl-1-cyclopentanecarboxamide as a novel scaffold for highly potent CC chemokine receptor 2 antagonists.

M. Maccoss, G. Butora, W. Parsons, 2007, Journal of medicinal chemistry.

Substituted imidazoles as glucagon receptor antagonists.

M. Maccoss, S. O'keefe, S. D. de Laszlo, 2001, Bioorganic & medicinal chemistry letters.

Direct sulfonylation of anilines mediated by visible light† †Electronic supplementary information (ESI) available. See DOI: 10.1039/c7sc03891g

M. Maccoss, C. Schofield, M. Willis, 2017, Chemical science.

1,2,3-Trisubstituted cyclohexyl substance P antagonists: Significance of the ring nitrogen in piperidine-based NK-1 receptor antagonists

C. Strader, D. Underwood, M. Maccoss, 1995 .

Potent 1,3,4-trisubstituted pyrrolidine CCR5 receptor antagonists: effects of fused heterocycles on antiviral activity and pharmacokinetic properties.

Joseph Kessler, Anthony Carella, D. Hazuda, 2005, Bioorganic & medicinal chemistry letters.

Characterization of Resistance to Non-obligate Chain-terminating Ribonucleoside Analogs That Inhibit Hepatitis C Virus Replication in Vitro*

D. Hazuda, R. Cortese, J. Tomassini, 2003, Journal of Biological Chemistry.

Evaluation of pyrrolidin-2-imines and 1,3-thiazolidin-2-imines as inhibitors of nitric oxide synthase.

M. Maccoss, S. Grant, T. Kelly, 2004, Bioorganic & medicinal chemistry letters.

Facile detritylation of nucleoside derivatives by using trifluoroacetic acid

M. Maccoss, Daniel J. Cameron, 1978 .

C−H Cyanation of 6‐Ring N‐Containing Heteroaromatics

M. Maccoss, C. Schofield, M. Willis, 2017, Chemistry.

Annelated piperazinyl‐7,8‐dihydro‐6H‐thiopyrano[3,2‐d]pyrimidines

M. Maccoss, B. Arison, R. Tolman, 1990 .

α-Aminothiazole-γ-aminobutanoic amides as potent, small molecule CCR2 receptor antagonists

M. Maccoss, W. Parsons, Changyou Zhou, 2007 .

1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists. Part 1: discovery of the pyrrolidine scaffold and determination of its stereochemical requirements.

M. Maccoss, J. Demartino, L. Malkowitz, 2001, Bioorganic & medicinal chemistry letters.

Structure-activity relationship of purine ribonucleosides for inhibition of hepatitis C virus RNA-dependent RNA polymerase.

Quanlai Song, Jie Xia, Daniel R McMasters, 2004, Journal of medicinal chemistry.

Inhibition of Hepatitis C Virus RNA Replication by 2′-Modified Nucleoside Analogs*

Lawrence C Kuo, Giovanni Migliaccio, L. Kuo, 2003, The Journal of Biological Chemistry.

Synthesis and evaluation of optically pure dioxolanes as inhibitors of hepatitis C virus RNA replication.

J. Tomassini, M. Maccoss, D. Olsen, 2003, Bioorganic & medicinal chemistry letters.

1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists. Part 3: polar functionality and its effect on anti-HIV-1 activity.

D. Hazuda, W. Schleif, E. Emini, 2002, Bioorganic & medicinal chemistry letters.

Synthesis and biological evaluation of nucleosides containing 8-amino-imidazo[1,2-α]pyrazine as an isosteric replacement for adenine†‡

J. Springer, E. Emini, M. Maccoss, 1993 .

A “GEOMETRY-ONLY“ 1 H NMR METHOD FOR DETERMINATION OF THE ANOMERIC CONFIGURATION OF RIBOFURANOSYL COMPOUNDS

M. Maccoss, M. Robins, 1978 .

Syntheses of all Four Possible Diastereomers of the Acyclonucleoside 9‐(1,3,4‐Trihydroxy‐2‐butoxymethyl)guanine from Carbohydrate Precursors.

M. Maccoss, R. Tolman, A. Chen, 1985 .

1-β-D-Arabinofuranosylcytosine-Phospholipid Conjugates As Prodrugs of Ara-C

M. Maccoss, C. West, C. Hong, 1984 .

Phospholipid-nucleoside conjugates. 3. Syntheses and preliminary biological evaluation of 1-beta-D-arabinofuranosylcytosine 5'-monophosphate-L-1,2-dipalmitin and selected 1-beta-D-arabinofuranosylcytosine 5-diphosphate-L-1,2-diacylglycerols.

M. Maccoss, R. Ross, C. West, 1982, Journal of medicinal chemistry.

METHYLATION EFFECTS ON NUCLEIC ACID CONFORMATIONS

S. Danyluk, M. Maccoss, C. Ainsworth, 1978 .

Stereochemical considerations in the enzymatic phosphorylation and antiviral activity of acyclonucleosides. I. Phosphorylation of 2'-nor-2'-deoxyguanosine.

J. D. Karkas, M. Maccoss, R. Tolman, 1987, Biochimica et biophysica acta.

Binding of 2-aryl-4-(piperidin-1-yl)butanamines and 1,3,4-trisubstituted pyrrolidines to human CCR5: a molecular modeling-guided mutagenesis study of the binding pocket.

M. Maccoss, J. Demartino, C. L. Lynch, 2003, Biochemistry.

Oxygen-17 NMR of nucleosides. II: Hydration and self-association of uridine derivatives

S. Danyluk, M. Maccoss, H. Schwartz, 1983 .

DNA BREAKAGE CAUSED BY 334‐nm ULTRAVIOLET LIGHT IS ENHANCED BY NATURALLY OCCURRING NUCLEIC ACID COMPONENTS AND NUCLEOTIDE COENZYMES

M. Maccoss, M. Peak, J. G. Peak, 1984, Photochemistry and photobiology.

The elusive 8-fluoroadenosine : a simple non-enzymatic synthesis and characterization

M. Maccoss, G. Butora, G. Doss, 2007 .

In vitro and in vivo predictors of the anti-emetic activity of tachykinin NK1 receptor antagonists.

M. Maccoss, R. Hargreaves, C. Swain, 1997, European journal of pharmacology.

Cyclopentane-based human NK1 antagonists. Part 1: discovery and initial SAR.

J. Metzger, M. Maccoss, D. Macintyre, 2006, Bioorganic & medicinal chemistry letters.

Synthesis of the chiral acyclonucleoside antiherpetic agent (S)-9-(2,3-dihydroxy-1-propoxymethyl)guanine

M. Maccoss, R. Tolman, A. Chen, 1985 .

Synthesis and biological evaluation of 5R- and 5S-methyl substituted D- and L-configuration 1,3-dioxolane nucleoside analogs.

W. Schleif, J. Tomassini, M. Maccoss, 2004, Bioorganic & Medicinal Chemistry.

Synthesis and evaluation of S-acyl-2-thioethyl esters of modified nucleoside 5'-monophosphates as inhibitors of hepatitis C virus RNA replication.

P. D. Cook, J. Tomassini, M. Maccoss, 2005, Journal of medicinal chemistry.

17O NMR of nucleosides. 3 —Chemical shifts of substituted uridines and ribothymidines

S. Danyluk, M. Maccoss, H. Schwartz, 1985 .

M. Maccoss, M. Robins, G. Ramani, 1976, Journal of the American Chemical Society.

Antiviral Efficacy upon Administration of a HepDirect Prodrug of 2′-C-Methylcytidine to Hepatitis C Virus-Infected Chimpanzees

M. Erion, P. D. van Poelje, M. Maccoss, 2009, Antimicrobial Agents and Chemotherapy.

Synthetic, Biochemical and Antiviral Aspects of Selected Acyclonucleosides and Their Derivatives.

J. D. Karkas, M. Maccoss, R. Tolman, 1986 .

Inhibitory Effect of 2′-Substituted Nucleosides on Hepatitis C Virus Replication Correlates with Metabolic Properties in Replicon Cells

J. Tomassini, M. Maccoss, G. Migliaccio, 2005, Antimicrobial Agents and Chemotherapy.

Chapter Three - A Career in Medicinal Chemistry—A Journey in Drug Discovery

M. Maccoss, 2013 .

Conformational characteristics of rigid cyclic nucleotides. 3. The solution conformation of. beta. -lyxonucleoside cyclic 2',5'- and 3',5'-monophosphates and of. cap alpha. -arabinonucleoside cyclic 2',5'-monophosphates. Implications for evaluation of the solution properties of nucleoside analogues

S. Danyluk, M. Maccoss, G. Leo, 1980 .

A new synthetic use of nucleoside N1-oxides

M. Maccoss, E. Ryu, Robert S. White, 1980 .

Proton magnetic resonance studies of 9-(β-d-xylofuranosyl)adenine 3′,5′-cyclic monophosphate and 9-(β-d-arabinofuranosyl)adenine 2′,5′-cyclic monophosphate

S. Danyluk, M. Maccoss, M. Robins, 1978 .

M. Maccoss, M. Robins, 1977, Journal of the American Chemical Society.

Influence of uracil photohydrate formation on the conformational properties of heterodinucleoside monophosphates

S. Danyluk, M. Maccoss, F. Ezra, 1980 .

M. Maccoss, M. Robins, G. Ramani, 1977 .

The treatment of intravenously implanted Lewis lung carcinoma with two sustained release forms of 1-beta-D-arabinofuranosylcytosine.

M. Maccoss, Y. Rahman, E. A. Cerny, 1984, European journal of cancer & clinical oncology.

NMR Investigations of the Solution Conformations of Deoxynucleotidyl (3′-5′) Arabinonucleosides

C. L. Bell, S. Danyluk, M. Maccoss, 1986 .

Synthesis of deoxyribonucleotidyl(3'5')arabinonucleosides

C. L. Bell, S. Danyluk, M. Maccoss, 1983 .

M. Maccoss, J. Wilson, M. Robins, 1977, Journal of the American Chemical Society.

3'-O-aminoacyl-2'-deoxyadenosines and 2'-O-aminoacyl-3'-deoxyadenosines related to charged transfer ribonucleic acid termini.

M. Maccoss, R. Jones, M. Robins, 1974, Biochemistry.

Efficacy of 2'-nor-cyclicGMP in treatment of experimental herpes virus infections.

J. D. Karkas, M. Maccoss, M. Davies, 1986, Antiviral research.

Conformational characteristics of rigid cyclic nucleotides. 2. The solution conformation of alpha-nucleoside 3', 5'-cyclic monophosphates and the role of the 2'-hydroxyl group.

S. Danyluk, M. Maccoss, M. Robins, 1977, Journal of the American Chemical Society.

Synthetic analogues of polynucleotides. Part IX. Synthesis of 3′-O-carboxymethyl-2′-deoxyribonucleosides and their use in the synthesis of an analogue of 2′-deoxyadenylyl-(3′→ 5′-)-thymidine 3′-phosphate

R. T. Walker, M. Maccoss, M. Edge, 1973 .

Concise preparation of 8-trifluoromethyltetrahydro-6H-pyrido [1,2-a] pyrazine-6-one

M. Maccoss, G. Butora, D. Guiadeen, 2009 .

Novel methods to functionalize thiazolo[4,5-c]pyridines

M. Maccoss, A. Arasappan, F. G. Njoroge, 2010 .

Synthesis and structure determination of [8(-13)C]guanosine 5'-diphosphate.

M. Maccoss, M. Poe, J. Germershausen, 1987, Analytical biochemistry.

M. Maccoss, M. Robins, J. Wilson, 1977 .

Mechanism of inhibition of human leucocyte elastase by beta-lactams. 3. Use of electrospray ionization mass spectrometry and two-dimensional NMR techniques to identify beta-lactam-derived E-I complexes.

D. Underwood, M. Maccoss, R. Chabin, 1995, Biochemistry.

The Synthesis and Preliminary Biological Evaluations of Selected Analogues of the Potent Broad-Spectrum Antiviral Agent Ganciclovir 1′,3′-Cyclic Monophosphate1 (2′-Nor-cGMP)

J. D. Karkas, M. Maccoss, R. Tolman, 1989 .

Comparison of the modes of antiviral action of 2'-nor-deoxyguanosine and its cyclic phosphate, 2'-nor-cyclic GMP

J. D. Karkas, M. Maccoss, R. Tolman, 1986, Antimicrobial Agents and Chemotherapy.

OXYGEN-17 NMR OF NUCLEOSIDES. 2. HYDRATION AND SELF-ASSOCIATION OF URIDINE DERIVATIVES

S. Danyluk, M. Maccoss, H. Schwartz, 1983 .

17O NMR spectroscopy of nucleoside derivatives; bonding characteristics of pyrimidine carbonyls

S. Danyluk, M. Maccoss, H. Schwartz, 1980 .

Synthetic analogues of polynucleotides. X. The synthesis of poly-(3'-O-carboxymethyl-2'-deoxyadenosine) and its interaction with polynucleotides.

R. T. Walker, M. Maccoss, A. S. Jones, 1973, Biochimica et biophysica acta.

CONFORMATIONAL CHARACTERISTICS OF RIGID CYCLIC NUCLEOTIDES. 3. THE SOLUTION CONFORMATION OF β-LYXONUCLEOSIDE CYCLIC 2′,5′- AND 3′,5′-MONOPHOSPHATES AND OF α-ARABINONUCLEOSIDE CYCLIC 2′,5′-MONOPHOSPHATES. IMPLICATIONS FOR EVALUATION OF

S. Danyluk, M. Maccoss, G. Leo, 1981 .

M. Maccoss, M. Robins, 1977 .

Novel, Orally Bioavailable γ-Aminoamide CC Chemokine Receptor 2 (CCR2) Antagonists

M. Maccoss, W. Parsons, S. Mills, 2006 .

Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 4: synthesis and structure-activity relationships for 1-[N-(methyl)-N-(phenylsulfonyl)amino]-2-(phenyl)-4-(4-(N-(alkyl)-N-(benzyloxycarbonyl)amino)piperidin-1-yl)butanes.

E A Emini, D. Hazuda, W. Schleif, 2001, Bioorganic & medicinal chemistry letters.

Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 3: a proposed pharmacophore model for 1-[N-(methyl)-N-(phenylsulfonyl)amino]-2-(phenyl)-4-[4-(substituted)piperidin-1-yl]butanes.

M. Maccoss, J. Demartino, P E Finke, 2001, Bioorganic & medicinal chemistry letters.

Antagonists of the human CCR5 receptor as anti-HIV-1 agents. part 1: discovery and initial structure-activity relationships for 1 -amino-2-phenyl-4-(piperidin-1-yl)butanes.

E A Emini, D. Hazuda, W. Schleif, 2001, Bioorganic & medicinal chemistry letters.

Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 2: structure-activity relationships for substituted 2-Aryl-1-[N-(methyl)-N-(phenylsulfonyl)amino]-4-(piperidin-1-yl)butanes.

E A Emini, D. Hazuda, W. Schleif, 2001, Bioorganic & medicinal chemistry letters.

Inhibition of stromelysin-1 (MMP-3) by P1'-biphenylylethyl carboxyalkyl dipeptides.

M. Maccoss, J. W. Becker, W. Hagmann, 1997, Journal of medicinal chemistry.

M. Maccoss, M. Robins, A. S. Lee, 1976, Biochemical and biophysical research communications.

Synthesis of New Imidazo(1,2‐b)pyridazine Isosteres of Potent Imidazo( 4,5‐b)pyridine Angiotensin II Antagonists

W. Greenlee, R. Chang, V. J. Lotti, 1994 .

The enzymatic synthesis of ATP analogues.

M. Maccoss, D. Johnson, S. Narindrasorasak, 1976, Biochemical and biophysical research communications.

1,3,4 Trisubstituted pyrrolidine CCR5 receptor antagonists bearing 4-aminoheterocycle substituted piperidine side chains.

Karen Holmes, Joseph Kessler, Anthony Carella, 2003, Bioorganic & medicinal chemistry letters.

1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists. Part 2: lead optimization affording selective, orally bioavailable compounds with potent anti-HIV activity.

D. Hazuda, W. Schleif, E. Emini, 2001, Bioorganic & medicinal chemistry letters.

Expression and Immunoaffinity Purification of Human Inducible Nitric-oxide Synthase

M. MacCoss, P. Griffin, J. Weidner, 1996, The Journal of Biological Chemistry.

Nonpeptide angiotensin II antagonists derived from 4H-1,2,4-triazoles and 3H-imidazo[1,2-b][1,2,4]triazoles.

R. Chang, V. J. Lotti, M. Maccoss, 1993, Journal of medicinal chemistry.

Synthesis and study of alendronate derivatives as potential prodrugs of alendronate sodium for the treatment of low bone density and osteoporosis.

M. Maccoss, P. Váchal, F. Kesisoglou, 2006, Journal of medicinal chemistry.

A facile synthesis of the novel neurokinin A antagonist SR 48968

M. Maccoss, J. Hale, P. Finke, 1993 .

Substituted N-(3,5-dichlorobenzenesulfonyl)-L-prolyl-phenylalanine analogues as potent VLA-4 antagonists.

M. Maccoss, W. Hagmann, K. Lyons, 2002, Bioorganic & medicinal chemistry letters.

Highly constrained bicyclic VLA-4 antagonists.

M. Maccoss, Gail Forrest, W. Hagmann, 2007, Bioorganic & medicinal chemistry letters.

Substituted 3-amino biaryl propionic acids as potent VLA-4 antagonists.

M. Maccoss, W. Hagmann, K. Lyons, 2002, Bioorganic & Medicinal Chemistry Letters.

Cyclic hydroxyamidines as amide isosteres: discovery of oxadiazolines and oxadiazines as potent and highly efficacious γ-secretase modulators in vivo.

Lynn A. Hyde, W. Greenlee, Xiaohong Zhu, 2012, Journal of medicinal chemistry.

NK2 receptors mediate plasma extravasation in guinea‐pig lower airways

M. Maccoss, C. Brideau, I. Rodger, 1993, British journal of pharmacology.

Modulating Target Protein Biology Through the Re-mapping of Conformational Distributions Using Small Molecules

Alastair D G Lawson, Jiye Shi, M. Maccoss, 2021, Frontiers in Chemistry.

Synthesis and SAR of geminal substitutions at the C5' carbosugar position of pyrimidine-derived HCV inhibitors.

X. Tong, M. Maccoss, N. Bansal, 2012, Bioorganic & medicinal chemistry letters.

Synthesis and SAR of pyridothiazole substituted pyrimidine derived HCV replication inhibitors.

X. Tong, M. Maccoss, N. Bansal, 2012, Bioorganic & medicinal chemistry letters.

1,3,4-Trisubstituted Pyrrolidine CCR5 Receptor Antagonists. Part 1. Discovery of the Pyrrolidine Scaffold and Determination of Its Stereochemical Requirements.

M. Maccoss, J. Demartino, L. Malkowitz, 2001 .

Discovery of human CCR5 antagonists containing hydantoins for the treatment of HIV-1 infection.

D. Hazuda, W. Schleif, E. Emini, 2001, Bioorganic & medicinal chemistry letters.

Design, synthesis, and SAR of heterocycle-containing antagonists of the human CCR5 receptor for the treatment of HIV-1 infection.

D. Hazuda, W. Schleif, E. Emini, 2001, Bioorganic & medicinal chemistry letters.

Distinct mechanism for antidepressant activity by blockade of central substance P receptors.

R G Hill, David J. Smith, J. Feighner, 1998, Science.

2(S)-((3,5-bis(trifluoromethyl)benzyl)-oxy)-3(S)-phenyl-4- ((3-oxo-1,2,4-triazol-5-yl)methyl)morpholine (1): a potent, orally active, morpholine-based human neurokinin-1 receptor antagonist.

C. Strader, J. Metzger, M. Maccoss, 1996, Journal of medicinal chemistry.

Structural optimization affording 2-(R)-(1-(R)-3, 5-bis(trifluoromethyl)phenylethoxy)-3-(S)-(4-fluoro)phenyl-4- (3-oxo-1,2,4-triazol-5-yl)methylmorpholine, a potent, orally active, long-acting morpholine acetal human NK-1 receptor antagonist.

J. Metzger, M. Maccoss, D. Macintyre, 1998, Journal of medicinal chemistry.

Phosphorylated morpholine acetal human neurokinin-1 receptor antagonists as water-soluble prodrugs.

J. Metzger, M. Maccoss, D. Macintyre, 2000, Journal of medicinal chemistry.

Inhibition of nitric oxide synthase by benzoxazolones

M. Maccoss, S. Grant, Shrenik K. Shah, 1997 .

N-(arylacetyl)-biphenylalanines as potent VLA-4 antagonists.

Bing Li, M. Maccoss, S. D. de Laszlo, 2002, Bioorganic & medicinal chemistry letters.

Supporting Information Synthesis and Study of Alendronate Derivatives as Potential Prodrugs of Alendronate Sodium; for the Treatment of Low Bone Density and Osteoporosis

M. Maccoss, F. Kesisoglou, J. Hale, 2006 .